China National Pharmaceutical Group's performance report: Net profit in 2025 was 944 million yuan, a year-on-year decrease of 12.85%.

Guoyao Xindai released its 2025 performance report on January 26. In 2025, the total operating income reached 9.363 billion yuan, a decrease of 14.4% compared to the previous year; the net profit attributable to shareholders of the listed company was 944 million yuan, a decrease of 12.85% year-on-year; and the basic earnings per share were 0.7041 yuan. During the reporting period, the demand for pharmaceutical intermediates and raw materials was affected by the market competition, leading to a decrease in sales volume and prices of some key products in the penicillin and potassium clavulanate series, resulting in a decline in the overall revenue of this sector; the income of formulated products also shrank year-on-year under the impact of normalized centralized procurement and price reduction. Due to fluctuations in the prices of pharmaceutical intermediates and raw materials and the impact of centralized procurement of formulated products, the overall gross profit margin of the company decreased by 6.91 percentage points year-on-year.